



Ettore Silvagni

WORK EXPERIENCE

[01/11/2018 – Current] **PhD Student in Molecular Medicine**

City: Ferrara

Country: Italy

Main activities and responsibilities:

[22/11/2018 – 31/10/2021] **Clinical collaboration as rheumatologist at Rheumatology Unit, Department of Medical Sciences, University of Ferrara, St. Anna Hospital, Cona, Ferrara (FE), Italy.**

City: Ferrara

Country: Italy

[01/11/2018 – 31/10/2021] **Visiting scientist at Department of Medical Sciences, University of Ferrara, Paolo Pinton Lab, Signal Transduction Lab, Ferrara (FE), Italy.**

City: Ferrara

Country: Italy

Main activities and responsibilities:

EDUCATION AND TRAINING

[01/10/2006 – 22/10/2012] **University of Medicine and Surgery Graduation, Ferrara (FE), Italy: magna cum laude (22/10/2012).**

Clinical Qualification, 19/02/2013 (N.4818)

Ordine dei Medici Chirurghi ed Odontoiatri, Ferrara Province

[08/08/2013 – 08/08/2018] **Graduation in Rheumatology, University of Modena and Reggio Emilia: magna cum laude (08/08/2018).**

[01/02/2019 – 30/04/2019] **Research fellowship at Leiden University Medical Centre (LUMC), Rheumatology Unit, Leiden, NL**

[01/11/2019 – Current] **Member of "Gruppo di studio della Società italiana di reumatologia (SIR) sul lupus neuropsichiatrico"**

Italian Society for Rheumatology

[01/07/2021 – Current] **Member of the Steering Committee of "Gruppo di studio della Società italiana di reumatologia (SIR) sul lupus neuropsichiatrico"**
Italian Society for Rheumatology

Research projects participation

Main subject / occupational skills covered:

1) SELECTIVE JAK INHIBITION AT SYNOVIAL LEVEL: UNVEILING THE EFFECT OF UPADACITINIB IN REFRACTORY RHEUMATOID ARTHRITIS. A PILOT IN VITRO STUDY - A.O.U. S.Anna, Università' degli Studi di Ferrara (from 12/2020).

2) IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY - awaiting AIFA Commission approval.

3) EVALUATION OF IN VITRO SYNOVIAL FUNCTIONAL RESPONSE PROFILING FOR PRECISION MEDICINE IN CHRONIC INFLAMMATORY ARTHRITIS - A.O.U. S.Anna, Università' degli Studi di Ferrara (from 04/2021).

4) Sub-investigator «FATTORI DI RISCHIO CLINICI ED ECOGRAFICI DELLO SVILUPPO DI ARTRITE PSORIASICA IN PAZIENTI PSORIASICI CON E SENZA ARTRALGIE». A.O.U. S.Anna, Università' degli Studi di Ferrara, P.I. Dott. A.Zabotti, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), from 10/2020.

2) Sub-investigator «RUOLO DELL'ECOGRAFIA MUSCOLO-SCHELETRICA NEL TRATTAMENTO DEL PAZIENTE AFFETTO DA ARTRITE PSORIASICA» A.O.U. S.Anna, Università' degli Studi di Ferrara, P.I. Dott. A.Zabotti, Prof. M. Piga, Società Italiana di Reumatologia, from 09/2019.

3) Sub-investigator «ALGORITHM TO INTEGRATE ULTRASONOGRAPHY IN THE DIAGNOSTIC PROCESS OF DIFFERENTIAL DIAGNOSIS OF INFLAMMATORY ARTHROPATHY IN CLINICAL PRACTICE» A.O.U. S.Anna, Università' degli Studi di Ferrara, P.I. Prof. C.A. Scirè, Società Italiana di Reumatologia, from 11/2020.

4) Sub-investigator «REGISTRO ITALIANO DI PAZIENTI CON LES - LIRE (LUPUS ITALIAN REGISTRY)» A.O.U. S.Anna, Università' degli Studi di Ferrara, P.I. Prof. A. Doria, Società Italiana di Reumatologia, from 11/2019.

5) Sub-investigator «GRUPPO DI STUDIO SIR SUL LUPUS ERITEMATOSO SISTEMICO DI RECENTE INSORGENZA PROTOCOLLO EARLY LUPUS 2.0». A.O.U. S.Anna, Università' degli Studi di Ferrara, P.I. Prof. G.D. Sebastiani, Società Italiana di Reumatologia, from 07/2021.

7) Sub Investigator "Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus", A.O.U. S.Anna, Università' degli Studi di Ferrara (2016-2017);

8) Sub investigator "A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus" A.O.U. S.Anna, Università' degli Studi di Ferrara (2016);

Sub investigator "Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis (SELUNE)" A.O.U. S.Anna, Università' degli Studi di Ferrara (2021);

Sub investigator "A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)" A.O.U. S.Anna, Università' degli Studi di Ferrara (2021).

Scientific Awards

Main subject / occupational skills covered:

2017 - Awarded by the Italian Society for Rheumatology for the best English oral presentation at the 54° Annual Congress of the Italian Society for Rheumatology, hold in Rimini (RN), Italy.

2018 - Awarded by the European League against Rheumatism (EULAR) with the EULAR scientific training bursary, for the project "Changes in cerebral diffusivity parameters in Neuro-Psychiatric Systemic Lupus Erythematosus: longitudinal analysis of diffusion tensor brain Magnetic Resonance Imaging".

2018 - Awarded by the Italian Society for Rheumatology for the best Poster Tour presentation at the 55° Annual Congress of the Italian Society for Rheumatology, hold in Rimini (RN), Italy.

2019 - Awarded by the Italian Society for Rheumatology for the best English oral presentation at the 56° Annual Congress of the Italian Society for Rheumatology, hold in Rimini (RN), Italy.

2020 - Awarded by Gruppo LES Italiano for participation at European Lupus Meeting.

2020 - Awarded by Abbvie for Investigator Initiated Support (2020-2022) - "SELECTIVE JAK INHIBITION AT SYNOVIAL LEVEL: UNVEILING THE EFFECT OF UPADACITINIB IN REFRACTORY RHEUMATOID ARTHRITIS. A PILOT IN VITRO STUDY".

Scientific Profile

Main subject / occupational skills covered:

Orcid Id: <https://orcid.org/0000-0001-7654-8222>

Web of Science Publons profile: <https://publons.com/researcher/4356947/ettoresilvagni/>

Scopus profile: <https://www.scopus.com/authid/detail.uri?authorId=57191738677>

Scientific production and Bibliometric Indicators (calculated as of 20/10/2021)

Total number of publications in international journals with Referees board reported on PubMed: 23

Number of publications accepted in international journals with Referees college (pending publication): 2

Number of publications in which the author has a leadership function (first / last author and / or corresponding author): 10 (43%)

Total number of citations: 244 (source Scopus, 20/10/2021)

Average number of citations per publication: 10.6

Total IF: 120,060

Mean IF per publication (Pubmed and / or Scopus): 5,220

Hirsch index / H-index: 10 (source Scopus, 20/10/2021)

Complete list of publications in international journals in chronological order - first part

Main subject / occupational skills covered:

1) The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. *J Autoimmun.* 2016 doi:10.1016/j.jaut.2016.06.013

2) Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. *RMD Open.* 2017 doi: 10.1136/rmdopen-2017-000523

3) Comparison of the risk of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. *Clin Exp Rheumatol.* 2018

4) One year in review 2018: novelties in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol.* 2018

5) Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECORD-linkage On Rheumatic Diseases study on health care administrative databases. *BMJ Open.* 2018 doi: 10.1136/bmjopen-2017-021447

6) Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence. *Clin Exp Rheumatol.* 2019

7) Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECORD linkage On Rheumatic Disease study of the Italian Society for Rheumatology. *Clin Exp Rheumatol.* 2019

8) Peripheral nervous system involvement in systemic lupus erythematosus: a retrospective study on prevalence, associated factors and outcome. *Lupus.* 2019 doi: 10.1177/0961203319828499.

9) One year in review 2019: novelties in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol.* 2019

10) Biological and synthetic target DMARDs in psoriatic arthritis. *Pharmacol Res.* 2019 doi: 10.1016/j.phrs.2019.104473.

11) Conventional brain Magnetic Resonance Imaging in the longitudinal evaluation of newly diagnosed Systemic Lupus Erythematosus patients: a retrospective analysis from a single-center cohort. *Lupus* 2020 doi: 10.1177/0961203320909955.

12) One year in review 2020: novelties in the treatment of rheumatoid arthritis. *Clin Exp Rheumatol.* 2020

13) The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. *Front Immunol.* 2020 doi: 10.3389/fimmu.2020.572876.

14) Methotrexate in Italian patients with Rheumatoid Arthritis (MITRA study): an observational study about the use of methotrexate in early RA patients and the adherence to the EULAR 2013 recommendations. A project of the Italian Society for Rheumatology. *Clin Exp Rheumatol.* 2021.

Complete list of publications in international journals in chronological order - second part

Main subject / occupational skills covered:

15) Longitudinal changes in cerebral white matter microstructure in newly diagnosed Systemic Lupus Erythematosus patients. 2021 doi: 10.1093/rheumatology/keaa677

16) The role of comorbidities on therapeutic persistence of biologic agents in rheumatoid arthritis: results from the RECOrd-linkage On Rheumatic Disease study on administrative healthcare databases. Scandinavian Journal of Rheumatology. 2021 doi: 10.1080/03009742.2020.1855365

17) Relevant domains and outcome measurement instruments in Neuropsychiatric Systemic Lupus Erythematosus: a systematic literature review. Rheumatology (Oxford). 2021 doi: 10.1093/rheumatology/keab324

18) Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. Lupus. 2021 doi: 10.1177/09612033211012470

19) SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. Lancet Rheumatol. 2021 doi: 10.1016/S2665-9913(21)00112-0

20) Serum Antibodies Against the Oncogenic Merkel Cell Polyomavirus Detected by an Innovative Immunological Assay With Mimotopes in Healthy Subjects. Front Immunol. 2021 doi: 10.3389/fimmu.2021.676627

21) From Bed to Bench and Back: TNF- α , IL-23/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis. Front. Pharmacol. 2021 Jun 15;12:672515. doi: 10.3389/fphar.2021.672515. Review.

22) One year in review 2021: novelties in the treatment of rheumatoid arthritis. Clin Expr Rheum 2021

23) Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. Arthritis Rheumatol. 2021 doi: 10.1002/art.41943

24) Rheumatoid arthritis and cardiovascular risk: retrospective matched-cohort analysis based on the RECORD study of the Italian Society for Rheumatology. Frontiers in Medicine. 2021 doi: 10.3389/fmed.2021.745601.

25) Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early Rheumatoid Arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients with Rheumatoid Arthritis (MITRA study). Clinical and Experimental

Rheumatology Accepted. 2021.

Editorial activity

Main subject / occupational skills covered:

1) Rheumalab (2020, <https://www.rheumalab.it/site/neuroimaging-nelle-patologiereumatiche/>). IL RUOLO DELLA RISONANZA MAGNETICA CEREBRALE CONVENZIONALE NEL LUPUS ERITEMATOSO SISTEMICO CON INTERESSAMENTO NEUROPSICHIATRICO. M. Borrelli, E. Silvagni, M. Govoni.

2) Collaborator: COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, Andreoli L, Caporali R, Gerli R, Sebastiani GD,

Valesini G, Sinigaglia L; Italian Registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753. Epub 2020 Jul 28. 3) Collaboratore: Factors associated with COVID-19-related death in people with

rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physicianreported registry. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Sirotych E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM; COVID-19 Global Rheumatology Alliance. Ann Rheum Dis. 2021 Jul;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27.

4) Peer reviewer: Clinical and Experimental Rheumatology ; Rheumatology (Oxf) (ongoing).

5) Review Editor: Frontiers in Medicine (ongoing).

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

English

LISTENING B1 READING C1 WRITING C1

SPOKEN PRODUCTION B1 SPOKEN INTERACTION B1

